Lee's Pharmaceutical Holdings Ltd
HKEX:950
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Lee's Pharmaceutical Holdings Ltd
Total Equity
Lee's Pharmaceutical Holdings Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Lee's Pharmaceutical Holdings Ltd
HKEX:950
|
Total Equity
HK$2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
3%
|
|
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
Total Equity
$4.9m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
G
|
Grand Pharmaceutical Group Ltd
HKEX:512
|
Total Equity
HK$17B
|
CAGR 3-Years
6%
|
CAGR 5-Years
9%
|
CAGR 10-Years
31%
|
|
|
Sino Biopharmaceutical Ltd
HKEX:1177
|
Total Equity
¥30.7B
|
CAGR 3-Years
1%
|
CAGR 5-Years
13%
|
CAGR 10-Years
17%
|
|
|
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
Total Equity
HK$51.4B
|
CAGR 3-Years
6%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
H
|
HUTCHMED (China) Ltd
HKEX:13
|
Total Equity
$1.2B
|
CAGR 3-Years
27%
|
CAGR 5-Years
21%
|
CAGR 10-Years
31%
|
|
Lee's Pharmaceutical Holdings Ltd
Glance View
Lee's Pharmaceutical Holdings Ltd. engages in the development, manufacture and sale of pharmaceutical products. The firm operates through two segments. Proprietary Products segment is engaged in the manufacture and sales of self-developed pharmaceutical products. Its proprietary products include Yallaferon, Livaracine and Slounase, among others. Licensed-in Products segment is engaged in the trading of licensed-in pharmaceutical products. Its licensed-in products include Ferplex and Zanidip, among others. The Company’s products are for cardiovascular and infectious diseases, dermatology, oncology, gynecology and ophthalmology, among others. The firm mainly operates businesses in China and Hong Kong.
See Also
What is Lee's Pharmaceutical Holdings Ltd's Total Equity?
Total Equity
2B
HKD
Based on the financial report for Dec 31, 2025, Lee's Pharmaceutical Holdings Ltd's Total Equity amounts to 2B HKD.
What is Lee's Pharmaceutical Holdings Ltd's Total Equity growth rate?
Total Equity CAGR 10Y
3%
Over the last year, the Total Equity growth was 24%. The average annual Total Equity growth rates for Lee's Pharmaceutical Holdings Ltd have been 2% over the past three years , -1% over the past five years , and 3% over the past ten years .
